Clostridium Diagnostics Market Size & Share, by Technology (Immunoassays-Based Clostridium Diagnostics, Molecular Clostridium Diagnostics); End User (Hospitals, Government Diagnostics Laboratories, Independent Laboratories); Product (Clostridium Difficile, Clostridium Botulinum, Clostridium Tetani, Clostridium Sordellii, Clostridium Perfringens) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5472
  • Published Date: Dec 22, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Clostridium Diagnostics Market size is estimated to reach USD 11 Billion by the end of 2036, expanding around 13% CAGR during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of clostridium diagnostics was close to USD 3 Billion. The major factor to dominate the market expansion is the growing prevalence of clostridium-related disease mostly in low-income of developing nations. However, its prevalence could be also observed in developed nations including the United States. For instance, in the case of the United States, over half of a million infections are caused by C. diff.

Hence, worldwide, Clostridium difficile continues to pose an important risk to public health. Additionally, there has been a surge in various different variants posing a risk to human health.  For instance, in addition to ribotype 027, which is known to be highly pathogenic, other strains such as 014/020, 017, 056, 106, and 078/126 have also been linked to C. difficile infection (CDI) and adverse health effects. The genetic composition, pathogenicity characteristics, antimicrobial susceptibility profiles, and geographic distribution of these strains vary, which may impact their capacity to spread disease and react to therapy.

Clostridium Diagnostics Market
Get more information on this report: Request Free Sample PDF

Clostridium Diagnostics Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2023)

~ USD 3 Billion

Forecast Year Market Size (2036)

~ USD 11 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Clostridium Diagnostics Market: Growth Drivers and Challenges


Growth Drivers

  • Rising Advancement in the Technology for Clostridium Testing - Without the aid of modern technology, diagnosing Clostridium is exceedingly challenging owing to its unusual symptoms. To determine the illness, sophisticated procedures such as enzymatic approaches, PCR (Polymerase Chain Reaction), and ELISA (Enzyme-Linked Immunosorbent Assay) are employed. Since PCR has a high sensitivity, it is employed in clinical laboratories and diagnostic centers.
  • Surge in Prevalence of Food Borne Illness - According to WHO, food is accountable for 420,000 deaths and 600 million incidents of foodborne illness worldwide each year. Children under the age of five contribute to 30% of foodborne deaths. WHO also estimates that consuming unsafe food contributes to the loss of 33 million years of good life annually worldwide. Hence, this has also increased demand for clostridium diagnostics market. The bacteria Clostridium perfringens represents one of the most frequent causes of food poisoning (foodborne disease). Spores are produced by these bacteria, and their coverings serve as a means of defense for the bacterium. C-perfringens has a capacity to grow and reproduce in specific environments, such as food stored at dangerous temperatures (40°F to 140°F, or 4 to 6°C).
  • Rising Use of AI to Launch Drugs for Clostridium Germs - Deployment of AI, along with proving to its benefits to every other industry is now showing great functionality in drug research. For instance, scientists at MIT and McMaster University have come across a novel antibiotic that can eradicate a particular kind of bacteria that causes a lot of illnesses that are resistant to medications, all due to the use of artificial intelligence algorithms. The novel medication was discovered by the researchers using a machine-learning algorithm they trained to determine whether a chemical molecule would restrict the growth of A. baumannii, out of a library of almost 7,000 possible medicinal compounds.


  • Rise in Cost of Technology Used to Detect and Treat Clostridium - The cost of the treatment employed for detection goes up since the sophisticated technology required to identify Clostridium is far more extensive than the immunoassay technique. Such life-saving medical treatment is extremely costly and out-of-pocket in developing and impoverished nations, and the majority of the population is unable to afford it due to low income and high-cost burden. Furthermore, a Clostridium difficile infection is an ongoing medical condition that frequently necessitates costly long-term care and specialist treatment. In addition, a lot of people with Clostridium difficile infections often have other conditions referred to as comorbidities, which drive up the cost of healthcare. For many patients, receiving treatment for clostridium difficile infection is severely hampered by its cost, especially in poor nations where insurance coverage is few and healthcare expenditures are high.
  • Lack of Awareness Among People Regarding the Prevalence of Clostridium
  • Lack of Resources Available

Clostridium Diagnostics Segmentation

Technology (Immunoassays-Based Clostridium Diagnostics, Molecular Clostridium Diagnostics)

The immunoassays-based clostridium segment in the clostridium diagnostics market is projected to hold 60% of the revenue share during the forecast period. The major factor to influence the growth of the market is the rising use of antibiotics. A third (33%) of respondents to a WHO/Europe poll that was performed uniformly across the 14 countries reported using antibiotics without a prescription. Furthermore, antimicrobial resistance (AMR) constitutes one of the top ten global health problems, according to the WHO, and it is thought that bacterial AMR causes 5 million deaths globally each year. The concerning truth is that by 2050, AMR might cause up to 10 million deaths annually if nothing is done. This is why the demand for immunoassays-based clostridium segment is growing. Further, they offer good specificity, are convenient to use, and produce results quickly and affordably. It has grown more challenging to assess whether a patient needs therapy since a growing percentage of individuals with positive molecular testing for CDI do not appear to have the toxins that have traditionally defined the illness. Better outcomes and accurate diagnostics are driving demand for immunoassays, which will fuel market expansion over the projected timeframe.

End User (Hospitals, Government Diagnostics Laboratories, Independent Laboratories)

Clostridium diagnostics market from the hospitals segment is set to rise by gathering the highest revenue of about 50% over the forecast period. Hospitals have experienced this growth as a result of employing better diagnostic technology over time. The majority of hospitals have testing facilities on-site or in affiliation with another facility. The use of cutting-edge methods including immunoassay and molecular diagnostic technologies in hospitals has made it feasible to diagnose Clostridium in these clinical laboratories, which is further fostering the growth of this clostridium diagnostics market. Antibiotics such as vancomycin, carbapenems, benzylpenicillin, sulfonamides, tetracyclines, metronidazole, and metronidazole are also easily available in hospitals, which contributes to the segment's growth.

Our in-depth analysis of the global clostridium diagnostics market includes the following segments:


  • Immunoassays-Based Clostridium Diagnostics
  • Molecular Clostridium Diagnostics

End User

  • Hospitals
  • Government Diagnostics Laboratories
  • Independent Laboratories


  • Clostridium Difficile
  • Clostridium Botulinum
  • Clostridium Tetani
  • Clostridium Sordellii
  • Clostridium Perfringens

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Clostridium Diagnostics Industry - Regional Synopsis

North American Market Statistics

The North America clostridium diagnostics market is poised to hold 30% of the revenue share during the forecast period. This growth of this region’s market is set to be influenced by rising healthcare infrastructure. For instance, federal and household funding comprised the greatest portions of total health spending (33 and 28 percent, respectively).   18% of the total amount spent on health care was attributed to private company expenditure, 15% to state and local governments, and 7% to other private sources of income. Additionally, the pharmaceutical business in the United States produces numerous novel medications each year that offer significant medicinal benefits. Many of those medicines are pricey, which drives up the cost of healthcare for both the federal government and the private sector. Lawmakers have given thought to measures that would cut both federal drug spending and prescription prices. These regulations would most likely lessen the industry's motivation to create novel medications. Hence, with this the clostridium diagnostics market in the region is also projected to grow owing to the affordability of medication more people are estimated to opt for the diagnosis.

European Market Analysis

The Europe clostridium diagnostics market is also estimated to have notable growth during the forecast period. There has been shift in lifestyle in European people which is leading people to consume more health food. Additionally, this region has observed unhealthy practices of producing and storing food. Hence, these factors are leading cause of clostridium related illness in Europe which is further expected to influence the clostridium diagnostics market expansion.

Research Nester
Clostridium Diagnostics Market size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Clostridium Diagnostics Market

    • Cerebriu
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Diazyme Laboratories, Inc.
    • BioMerieux
    • Beckman Coulter, Inc.
    • F. Hoffmann-La Roche
    • Chrono-log Corporation
    • Hikma Pharmaceutical PLC
    • Pfizer Inc.
    • Baxter
    • DiaSorin SpA


In The News

  • Cerebriu, a company that offers artificial intelligence (AI) solutions for streamlining radiology processes, and Siemens Healthineers, the top producer of magnetic resonance imaging (MRI) scanners worldwide, have partnered to incorporate Cerebriu's unique Smart ProtocolTM for Brain MRI-workflow automation software into Siemens Healthineers' MRI equipment.
  • Diazyme Laboratories and Maccura Biotechnology announced a collaboration to launch an FDA EUA-approved SARS-COV-2 RT-PCR diagnostic test. Located in Poway, California, Diazyme Laboratories Inc. is a Life Science Affiliate of General Atomics. Using its patented enzyme and immunoassay technology, Diazyme creates user-friendly diagnostic test reagents that may be used with automated chemistry analyzers and chemiluminescence equipment.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5472
  • Published Date: Dec 22, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Ans: The major factors driving the growth of the market are rising advancement in technology for clostridium diagnostics, the surge in the prevalence of foodborne illness, and the rising use of AI to launch drugs for clostridium.

Ans: The market size of clostridium diagnostics is anticipated to attain a CAGR of 13% over the forecast period, i.e., 2024-2036.

Ans: The major players in the market are Cerebriu, Diazyme Laboratories, Inc., BioMerieux, Beckman Coulter, Inc. and others.

Ans: The hospitals segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

Ans: The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Clostridium Diagnostics Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying